It is known from the post-mortem studies of accidental death that atherosclerotic process begins in childhood and gradually progresses over decades. Only when the process leads to flow limiting stenosis as a gradual narrowing or when a thrombus forms at a site of plaque due to rupture or erosion, then the clinical cardiovascular event is manifested. Although only a certain percentage of people with underlying atherosclerosis become manifest, the greater degree of subclinical atherosclerosis is associated with greater chance of future events. The event could be sudden cardiac death at its extreme.

Hence there is a greater interest in identifying asymptomatic atherosclerosis process in an individual. They can be of candidate for intensive evidence-based medical interventions to reduce the risk of events. Imaging techniques is one way to define the cardiovascular risk assessment. However, the screening test should be cheap, safe, easy, and sensitive and should be decisive for the intervention that would change the natural history of the cardiovascular disease.

The ultrasound measurement of carotid intima-media thickness (CIMT) has withstood test of time as an important technique of measuring atherosclerotic burden. It has been more than three decades to know the value of CIMT in the risk prediction.

Anatomy

We are measuring the combined thickness of intima and media of common carotid artery of both sides. The right common carotid artery is a branch of innominate artery, also known as truncus brachiocephalicus, because it divides into common carotid artery (CCA) and subclavian artery. Left CCA directly originates from the aortic arch. The cervical course of CCA is medially located, slightly behind the internal jugular vein. It then bifurcates into internal carotid and external carotid arteries approximately at the level of fourth cervical vertebra. It is superficially located, straight and relatively long caliber making its measurement relatively easy.

Histologically there are three layers in the arteries:

1. Tunica intima: inner layer of endothelial cells
2. Tunica media: middle layer of longitudinal smooth muscle cells surrounded by connective tissues
3. Tunica adventitia/ externa: outer layer lying in the circumjacent tissue

Histopathology

Atherosclerosis process is regarded as systemic chronic inflammatory disease; the major impact of morbidity and mortality of it being the cardiovascular disease. The process of atherosclerotic vascular disease is viewed in a theory called “response to injury theory”. It says that a physical injury of endothelium is primarily responsible for the changes in vessel wall. In fact endothelial dysfunction is regarded as a functional trigger to atherosclerosis. LDL cholesterol gets in the endothelium and the following oxidative and enzymatic processes lead to series of changes that leads to different stages of development of atherosclerosis.

The early phase is hypertrophic response of medial cells, that can be assessed by carotid intima-media thickness (CIMT) measurement and later stages are mostly carotid plaques caused by inflammation, oxidation, and smooth muscle cell proliferation. Increased CIMT is typically seen in common carotid artery due to its flow dynamics, whereas plaques are particularly seen in internal carotid artery or carotid bulbs. As found in the studies, CIMT elevation are most often related to hypertension and stroke as there is stronger relationship of carotid plaques at carotid bulb or internal carotid artery to dyslipidemia and myocardial infarction.

CIMT measurements

Already in the 1980s Paulo Pignoli et al. could demonstrate a significant association between histological findings of in vitro study and ultrasound examination in the specimens.
They described a characteristic B-mode image of arterial wall consisting of two parallel echogenic lines separated by hypoechoic space. The combined width of carotid artery intima and media can be reliably visualized in nearly all subjects. Since then multiple studies have been carried out to study the association of CIMT with cardiovascular risk factors, extent and severity of atherosclerosis and cardiovascular and cerebrovascular events.

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Study Name</th>
<th>No of Participant</th>
<th>Age of participant</th>
<th>Primary Endpoints Measured at</th>
<th>Risk Estimation</th>
<th>Method of measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chambless et al. 1997</td>
<td>ARIC⁷</td>
<td>12,841</td>
<td>45–64 years</td>
<td>Fatal and nonfatal CV events</td>
<td>For CIMT &gt;1 vs. &lt;1 mm, HR 1.18 (1.06–1.32) in men and 1.42 (1.24–1.64) in women. (Adjusted for Diabetes, HDL-, LDL-cholesterol, hypertension, smoking status, study center, age and race)</td>
<td>CIMT = mean CIMT from 6 different segments</td>
</tr>
<tr>
<td>O’Leary et al. 1999</td>
<td>CHS⁸</td>
<td>4,476</td>
<td>72.5 years (mean age)</td>
<td>Myocardial infarction, stroke, combination of MI &amp; CVA</td>
<td>RR-combined endpoint CCA: 2.22 (1.58–3.13) for &gt;1.18 mm (highest) vs. &lt;0.87 mm (lowest CIMT-quintile); 2.47 (1.59–3.85) for &gt;1.81 mm (highest) vs. &lt;0.90 mm (lowest CIMT-quintile). (Adjusted for age, gender, blood pressure, smoking, Diabetes, atrial fibrillation)</td>
<td>Max. CIMT</td>
</tr>
<tr>
<td>Del Sol et al. 2002</td>
<td>Rotterdam⁹</td>
<td>1,721</td>
<td>&gt;55 years</td>
<td>Stroke, Myocardial Infarction</td>
<td>RR 1.41 (1.25–1.82) for stroke and 1.43 (1.16–1.78) for myocardial infarction</td>
<td>Max. CIMT</td>
</tr>
<tr>
<td>Lorenz et al. 2010</td>
<td>CAPS¹⁰</td>
<td>5,056</td>
<td>19–90 years</td>
<td>Combined endpoint of MI and Stroke</td>
<td>HR for CIMT-CCA &gt;0.79mm vs. &lt;0.63 mm 1.85 (1.09–1.51), HR for CIMT-CB &gt;0.79mm vs. &lt;0.63 mm 1.27 (0.80–1.99), HR for CIMT-ICA &gt;0.79 mm vs. &lt;0.63 mm 1.25 (0.84–1.86) (Adjusted for risk factors)</td>
<td>Mean far wall CIMT</td>
</tr>
<tr>
<td>Nambi et al. 2010</td>
<td>ARIC¹¹</td>
<td>13,145</td>
<td>45–64 years</td>
<td>Fatal and non-fatal CV events and revascularization</td>
<td>Men: CIMT increased AUC from 0.674 (only risk factors) up to 0.690 (95% CI for difference of the adjusted AUC: 0.009–0.022). Women: CIMT increased AUC from 0.759 (only risk factors) up to 0.762 (95% CI for difference of the adjusted AUC: −0.002–0.006).</td>
<td>Mean CIMT from 6 different segments</td>
</tr>
<tr>
<td>Plichart et al. 2011</td>
<td>Three-City¹²</td>
<td>5,895</td>
<td>65-85 years</td>
<td>Newly diagnosed CV disease</td>
<td>HR 5th vs. 1st quintile = 0.8; 95% CI = 0.3–1.2; P for trend &lt;0.48 (Adjusted for risk factors).</td>
<td>Mean far wall CIMT;</td>
</tr>
</tbody>
</table>

An increased age increases the CIMT value for a person. It has been described that CIMT increases at a rate of 0.007 per year with 5-year delay in women.¹⁸

**Technique of measurement:**

Ultrasound measurement is safe, cheap, relatively painless and quick way of examination without radiation exposure. Moreover it can be repeated over time and time. At present time B mode ultrasound can be used to see the artery wall changes via measurement of CIMT and plaques.

Given the technical limitation to image intima alone, combined thickness of intima and media is measured. It is measured as the distance between lumen-intima interface and media-adventitia interface.

Carotid plaques are the localized atherosclerotic substances that build up inside the carotid artery consisting of necrotic cells, lipids and cholesterol crystals. The plaques can cause stenosis, embolism, and thrombosis.

Carotid plaques differ from CIMT by an increase in CIMT about at least 0.5 mm compared to adjacent wall or increase in thickness more than 50% to adjacent wall as well as total thickness more than 1.5 mm, much higher value than CIMT alone.¹⁹

---

Fig 2: Ultrasound image showing measurement of near and far wall CIMT in the distal 1 cm of the CCA.⁷
Carotid intima-media thickness and coronary artery disease

The distal CCA is usually straight and relatively superficial so it is recommended to measure the last 1 cm of distal CCA. Values in percentiles by age, sex, and ethnicity such as ARIC applied in large epidemiological study, which reported CIMT more abundant atherosclerotic lesions.

Measurement Protocol:

The imaging protocol should follow the same method that is applied in large epidemiological study, which reported CIMT values in percentiles by age, sex, and ethnicity such as ARIC study. It is recommended to measure the last 1 cm of distal CCA. The distal CCA is usually straight and relatively superficial so it is easy to obtain consistent value. The far wall is chosen because it has limited movement, is of good size and is easily accessible; and hence technically easier, more reproducible and improves risk prediction. Several measurements are to be taken and then averaged to get the mean value.

In addition, since ultrasound beams are travelling from more echogenic to less echogenic area in the near wall, CIMT will be less accurate. In fact, one study near wall CIMT was 20% less than corresponding histology.

A circumferential scan of the extracranial carotid arteries is to be supplemented to find out any carotid plaques that measure more abundant atherosclerotic lesions.

Normal value of CIMT is difficult to obtain because the absolute values depends also on location of measurement (segment of artery, near or far wall), body habitus, ultrasound equipment used, imaging depth, off line recording system (automated or manual tracking), and imaging quality obtained. In general, values of CIMT more than 0.9 mm are considered abnormal. To be precise, the mean value > 75th percentile for the specific age, sex, ethnicity and side should be used.

These values are responsible for variations in CIMT values among different studies. So for the purpose of standardization, the far wall of distal 1 cm of CCA of both sides should be used in the clinical practice in three different angles and averaged value is to be compared.

Problems and Solution:

One challenge could be unable to get double line sign so as to define media-adventitia interface. It should be overcome by repeated attempts of imaging in different positions, moving transducers to more horizontal position and changing the focus and gain.

Another issue is tortuosity of CCA. Rotation and elongation of neck will straighten the vessel segment. If excessive respiratory movement is occurring and transition artifact from jugular vein is interfering, breath hold at mid inspiration will stabilize the image and then CIMT could be measured satisfactorily.

Using appropriate gain setting, linear array transducer of at least 7 MHz frequency at its fundamental frequency, proper time gain compensation settings are all important to have reliable and reproducible image.

In fact Velazquez et al reported a very high degree of inter-observer correlation (97.2%) if we follow the same standard protocol.

Clinical significance of CIMT:

Multiple epidemiological studies have shown that traditional as well as emerging cardiovascular risk factors are associated with increased CIMT. Age, hypertension, diabetes mellitus, dyslipidemia, smoking all have positive correlation with increased CIMT. Emerging risk factors including lipoprotein (a), oxidized LDL, and homocysteine are also shown to have positive correlation.

Inflammatory markers are associated with atherosclerosis and these markers do correlate with elevated CIMT values. Wang et al showed that elevated CIMT with C-reactive protein in women in Framingham Heart Study, even after adjustment of traditional risk factors. C-reactive protein was found to be associated with CIMT in Rotterdam study and could predict the progression as well. The constellation of cardiovascular risks with abdominal obesity, hypertension, hyperglycemia, hypertriglyceridemia, insulin resistance, known as metabolic syndrome has different perspective to CIMT value and is a subject of research. Disproportionate elevation in CIMT is found in patients with metabolic syndrome in a study using data from Baltimore Longitudinal Study of Aging. Even in young
population, people with metabolic syndrome had a higher CIMT value compared to control population.

A fact comes to our mind that the artery being imaged is not a coronary artery then how could carotid atherosclerosis predict coronary events. The notion is that atherosclerosis is a systemic disease. So coronary atherosclerosis assessed by CT coronary calcification and coronary angiography is found to be associated with increased CIMT and carotid plaques. In Rotterdam Calcification Study, in 2013 patients, carotid intima-media thickness and coronary calcium scores were significantly associated after adjustment of traditional CV risk factors including hypertension, diabetes, smoking and dyslipidemia.

In Muscatine study, these findings were found even in young patients of 33-42 years. CIMT remained to be associated with statistical significance in multivariate analysis. In another study by Kafetzakis et al, there was positive correlation of CIMT and significant coronary artery disease as assessed by coronary angiography having > 50% diameter stenosis. There was positive association with increased number of coronary artery involved.

558 patients were evaluated in a study by Kablak-Ziemcicka et al who found that an individual with CIMT value of > 1.15 mm had a 94% chance of having significant CAD.

All these findings produced the concept of CIMT as surrogate marker of CAD. We now know that atherosclerosis begins in early age and gradually progresses over years. Because of these long years of development of clinical CV events, occurrence of them takes years of follow up and lengthy expensive use of resources. So CIMT is often used in studies to assess the effect of pharmacological therapy in treatment of cardiovascular disease.

Pitt et al found the effect of amiodipine to regress CIMT whereas verapamil and probucol have been shown to decrease the progression of CIMT in different studies. Metoprolol succinate is also shown to significantly decrease CIMT and trends towards lower CV events. Pioglitazone has also to decrease CIMT in diabetic patients. In that study, in 173 diabetic patients, Pioglitazone decreased mean CIMT value by – 0.031 ± 0.014 mm at 6 months (P < 0.001) whereas there was no statistical significance with glimepiride. For mean follow up of 3.6 months, folic acid was not found to change CIMT value in chronic kidney disease patients.

HMG CoA reductase-inhibitors or statin group of drugs has most robust data for changes in CIMT. 919 people with hypercholesterolemia but asymptomatic were studied by Probstfield et al in which lovastatin significantly decreased mean CIMT as well as CV event rate and mortality. MacMohan et al studied in 552 people with history of CAD but average cholesterol level; pravastatin treated group had 0.014 mm less CIMT whereas placebo treated group had 0.048 mm increase in CIMT over a period of 4 years. Another study showed that more intense statin therapy decreases CIMT more aggressively. Smilde et al studied 325 patients with familial hypercholesterolemia in which 80 mg of atorvastatin decreased CIMT value by – 0.031 mm (95% CI – 0.031 to – 0.055; P < 0.0001) after two years of follow up. In ARBITER (arterial biology for investigations of the treatment effects of reducing cholesterol) trial, Taylor et al used 80 mg atorvastatin that decreased CIMT by – 0.034 ± 0.021 mm compared to 40 mg pravastatin (0.025 ± 0.017 mm) (P < 0.05) at follow up period of 1 year. Fibrates do not have same effect on decreasing CIMT values.

The future:

Although more than three decades already passed since the introduction of CIMT and its ability to predict future cardiovascular risk, it is not widely practiced. Moreover a number of pitfalls exists to make it a quality measurement that is consistent at both inter- and intra-observer level. Many issues regarding extensive imaging protocol can put the cost and available resources in question. Since it is fine measurement, 0.1 mm measurement differences can put patients in different risk categories, quality control is a definite prerequisite.

One of the best ways to apply cardiovascular prevention is measurement of CIMT in young people. If we can apply correctly about the correct prediction of risk of events before it occurs, we can apply the intense lifestyle and/or pharmacological interventions in the target groups. As views by Urbina et al few issues has to be solved in current CIMT knowledge in young. These include normative values in young, how to address in regard to body size and growth, and which segment provides best information.

CIMT is used as surrogate marker of cardiovascular events in many clinical trials. For that evidence that changes in CIMT should show parallel changes in CV events. Two meta-analyses show conflicting results with this regard. Consistent imaging protocols were not used in both meta-analyses and future studies will help to have definitive conclusion in this matter.

It seems that CIMT hold particular promise to risk categorization for those with intermediate risk using existing risk assessment method such as Framingham risk score. At the outset, the use of CIMT in risk profiling depends on balance between costs and effectiveness (events prevented, life gained, quality adjusted life years gained).

The Back Side:

Although several studies showed the predictive power of future cardiovascular events, there is little add on prognostic value when CIMT is combined with traditional risk factors score such as Framingham Risk Score. These views have been laid by two meta-analyses. Lorenz et al observed that by 0.1 mm increase in CIMT relative risk of CV event is increased by 1.15.

Den Ruijter et al found there is no additional event prediction by adding CIMT to conventional risk factors.

The 2010 ACC/AHA guideline recommended CIMT measurement for CVD risk assessment in intermediate risk asymptomatic patients as class IIa recommendation. However 2013 guideline is against its use for individual risk prediction.

These varying results and guideline recommendations are reflected by different parts of the artery imaged, plaques included or excluded; and the equipment and technical method of measurement. In fact the test had shown higher accuracy and reproducibility in the research settings when appropriately done according to strict protocol, accurate equipment and operator training. But the same is not reproduced in the clinical practice settings. All the available data are from the research studies following highly standardized protocols.

The elevated level of CIMT is regarded as the value exceeding 75th percentile value of population based study, but it must be identified to a particular carotid artery segment and ultrasound methodology to be used.

2013 ACC/AHA guideline tried to search for the evidence of reclassification or contribution of CIMT to the risk assessment to an asymptomatic adult male in routine clinical practice. The final conclusion made by the Work Group was, with concern of measurement quality, there was sufficient rationale to recommend against measuring CIMT in routine clinical practice for estimation of risk for the first cardiovascular events.

It seems that when the technology improves with finer resolution of ultrasound techniques or if we could find the correct way to find asymptomatic atherosclerotic process, which will be boon to the medical practice that would correctly identify those people who are going to have cardiovascular event in near future. Carotid intima media thickness is a promising one but still not yet validated to be useful at the moment.
Carotid intima-media thickness and coronary artery disease

References:


Nepalese Heart Journal 2018; 15(1): 9-15
Carotid intima-media thickness and coronary artery disease


36. Davis PH, Dawson JD, Mahoney LT, Lauer RM. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults: the Muscatine study. Circ 1999;100(8):838-842. https://doi.org/10.1161/01.CIR.100.8.838


45. Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol 1995;76(9):47C-53C. https://doi.org/10.1016/S0002-9149(95)00470-6


